ADVERTISEMENT
Getinge iCast Covered Stent System Considered Medically Necessary for Treatment of Iliac Arterial Occlusive Disease
Getinge announced Aetna, a leading health insurance benefits company in the United States, issued a Clinical Policy Bulletin (CPB) addressing peripheral vascular stents.
Aetna issued a revised CPB stating that the iCast covered stent system is considered medically necessary for the treatment of iliac arterial occlusive disease. The insurance provider previously designated the medical device as experimental and investigational.
The determination was based upon review in March 2024 of currently available clinical information, according to the CPB, including clinical outcome studies in the peer-reviewed published medical literature; regulatory status of the technology; evidence-based guidelines of public health and health research agencies; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas; and other relevant factors. The last CPB review of peripheral vascular stents was in October 2023.
“We are very pleased Aetna determined the iCast covered stent system to be medically necessary for the treatment of iliac arterial occlusive disease,” said Therese Mueller, Vice President of Sales, Acute Care Therapies at Getinge. “We are more thrilled that Aetna member benefit plans will include this new option for consideration when it comes to treatment of this serious and often painful condition.”
In March 2023, the iCast covered stent received premarket approval from the U.S. Food and Drug Administration (FDA) for the treatment of iliac arterial occlusive disease. As of November 2023, the system and full range of Getinge support materials and services are available to support physicians who treat patients affected by iliac arterial occlusive disease.
Find More:
The Latest Clinical & Industry News
Grand Rounds With Morton Kern, MD
